Author:
Pineda Carlos,Castañeda Hernández Gilberto,Jacobs Ira A.,Alvarez Daniel F.,Carini Claudio
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference72 articles.
1. Morrow T, Felcone LH. Defining the difference: what makes bologics unique. Biotechnol Healthc. 2004;1(4):24–9.
2. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol. 2010;28(9):917–24.
3. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel). 2012;5(4):353–68. doi: 10.3390/ph5040353 .
4. Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605. doi: 10.1016/S1470-2045(14)70365-1 .
5. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. SIlver Spring: U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2015 (last update Apr 2015). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf . Accessed 23 Mar 2015.
Cited by
92 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献